Ina - internexin neuronal intermediate filament protein, alpha Gene

Also Known as Nf66; Inexa; Intlaa; alpha-Inx

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 24503

Summary

Predicted to be a structural constituent of postsynaptic actin Cytoskeleton and structural constituent of postsynaptic intermediate filament Cytoskeleton. Involved in tissue regeneration. Is active in glutamatergic synapse and postsynaptic intermediate filament Cytoskeleton. Orthologous to human INA (internexin neuronal intermediate filament protein alpha). [provided by Alliance of Genome Resources, Apr 2022]

Ina Products (1)

mRNA Protein Name
NM_019128.5 NP_062001.2 alpha-internexin

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables protein binding IPI
IPI: Inferred from physical interaction
23452857 RGD
enables protein-containing complex binding IDA
IDA: Inferred from direct assay
9388258 RGD
Biological Process GO Annotation Evidence References Source
involved in tissue regeneration IEP
IEP: Inferred from expression pattern
12077192 RGD
Cellular Component GO Annotation Evidence References Source
is active in glutamatergic synapse IDA
IDA: Inferred from direct assay
9310396 RGD
is active in postsynapse IDA
IDA: Inferred from direct assay
9310396 RGD
is active in postsynaptic density, intracellular component IDA
IDA: Inferred from direct assay
9310396 RGD
is active in postsynaptic intermediate filament cytoskeleton IDA
IDA: Inferred from direct assay
9310396 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

alpha-internexin

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (4)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-B0280 Ranolazine Inhibitor 99.79% Yes
HY-17401 Ranolazine dihydrochloride 99.99% Yes
HY-108767 Insulin aspart ≥95.0% Unkown
HY-A0236 Aprindine Inhibitor 98.43% Unkown

Clinical Phase

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Phase
HY-148792 Relutrigine Inhibitor 99.33% Phase 3
HY-18600 Azimilide Inhibitor 99.01% Phase 3
HY-111245 AZD-1305 Inhibitor / Phase 2

Pre-clinical Phase

Bioactive Molecules (21)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-100001 SKF-96365 (hydrochloride) 99.93% Unkown
HY-110195 Smurf1-IN-A01 99.81% Unkown
HY-12593 GS967 Inhibitor 99.55% Unkown
HY-108579 UCL 1684 dibromide Inhibitor 98.03% Unkown
HY-18600A Azimilide dihydrochloride Inhibitor 98.17% Unkown
HY-N6868 Dimethyl lithospermate B Agonist 99.40% Unkown
HY-144652 IDO1-IN-19 Inhibitor 98.82% Unkown
HY-A0236A Aprindine hydrochloride Inhibitor 98.96% Unkown
HY-125942 SKF-96365 99.97% Unkown
HY-163549 APN-PEG5-VC-PAB-MMAE 95.19% Unkown
HY-B0280S2 Ranolazine-d3 Inhibitor 99.49% Unkown
HY-126005 VGSC blocker-1 Inhibitor / Unkown
HY-156976 Sulcardine Inhibitor / Unkown
HY-17401S Ranolazine-d8 dihydrochloride 99.0% Unkown
HY-18600AS Azimilide-d8 dihydrochloride Inhibitor / Unkown
HY-B0280S Ranolazine-d5 Inhibitor / Unkown
HY-RS06802 INA Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-156976A Sulcardine hydrochloride Inhibitor / Unkown
HY-B0280S1 Ranolazine-d8 Inhibitor 99.9% Unkown
HY-RS16782 Ina Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23222 Ina Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Inhibitory Antibodies (1)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P992387 INA01 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Ina NCBI NCBI:9118